6,076 Shares in Johnson & Johnson $JNJ Bought by Vista Capital Partners Inc.

Vista Capital Partners Inc. acquired a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 6,076 shares of the company’s stock, valued at approximately $1,609,000.

A number of other institutional investors have also recently bought and sold shares of the business. Astra Wealth Partners LLC raised its position in shares of Johnson & Johnson by 4.5% during the 3rd quarter. Astra Wealth Partners LLC now owns 1,385 shares of the company’s stock valued at $367,000 after acquiring an additional 60 shares during the last quarter. McElhenny Sheffield Capital Management LLC boosted its position in shares of Johnson & Johnson by 19.4% in the 3rd quarter. McElhenny Sheffield Capital Management LLC now owns 1,677 shares of the company’s stock worth $444,000 after purchasing an additional 273 shares during the last quarter. 10Elms LLP boosted its position in shares of Johnson & Johnson by 6.8% in the 3rd quarter. 10Elms LLP now owns 1,263 shares of the company’s stock worth $334,000 after purchasing an additional 80 shares during the last quarter. Aberdeen Group plc boosted its position in shares of Johnson & Johnson by 8.5% in the 3rd quarter. Aberdeen Group plc now owns 2,654,448 shares of the company’s stock worth $702,739,000 after purchasing an additional 207,390 shares during the last quarter. Finally, Stonebridge Financial Planning Group LLC grew its stake in shares of Johnson & Johnson by 2.6% during the third quarter. Stonebridge Financial Planning Group LLC now owns 2,529 shares of the company’s stock worth $670,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.0%

Shares of NYSE JNJ opened at $285.78 on Monday. The company’s fifty day moving average is $266.97 and its 200-day moving average is $249.85. The stock has a market cap of $687.95 billion, a price-to-earnings ratio of 43.30, a P/E/G ratio of 2.82 and a beta of 0.22. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the business earned $2.80 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on JNJ shares. Morgan Stanley cut their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research note on Thursday, October 15th. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research note on Monday, August 3rd. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Check Out Our Latest Research Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.